Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: J. Nelson who wrote (46)	11/20/1998 12:07:00 PM
From: MoneyMade	Read Replies (2) \| Respond to of 15987

PCS_W (SPRINT) rocking this A.M. -- Lehman said it started Sprint PCS with a buy rating and a 1999 price target of $21 a share. Estimates earnings per share at a loss of $6.18 in 1998 and a loss of $4.75 in 1999. -- Standard & Poor's said Thursday Sprint PCS would replace steel company Armco Inc (NYSE:AS - news) in the S&P 500 index.

To: J. Nelson who wrote (46)	11/20/1998 12:11:00 PM
From: MoneyMade	Respond to of 15987

SKYL...THIS JUST IN To: MoneyMade (who wrote...) From: XXXX Friday, Nov 20 1998 12:08PM ET hey.. news flash for your folks. i turned a bunch of shorters on to SKYL.. they are going to be all over it. tell your folks to get out if they haven't .. this one is heading down..

To: J. Nelson who wrote (46)	12/15/1998 3:07:00 PM
From: MoneyMade	Read Replies (3) \| Respond to of 15987

VRTX---Tuesday December 15, 2:08 pm Eastern Time Vertex says some tumors shrink in cancer study CAMBRIDGE, Mass., Dec 15 (Reuters) - Vertex Pharmaceuticals Inc. (Nasdaq:VRTX - news) said Tuesday that preliminary results of a Phase II trial show that tumors in some patients with advanced breast cancer shrank when the standard paclitaxel treatment was combined with the Vertex drug Incel. Vertex said that of 32 patients, a partial response (50 percent or more tumor regression) was noted in three patients, and a minor response (25 to 50 percent regression) was noted in one patient. Of these four patients, three had experienced tumor growth during a previous course of paclitaxel therapy. The study is part of a broad program evaluating Incel's potential to resensitize drug-resistant tumors to chemotherapy in a range of cancer types and therapeutic regimens. Vertex said treatment with Incel and paclitaxel has been well tolerated. With Incel coadministration, only half the standard dose of paclitaxel is necessary to achieve and maintain paclitaxel blood levels comparable to those produced using the higher usual dose of paclitaxel alone, it said. ''The potential of Incel to enhance or restore a therapeutic effect of paclitaxel is a promising finding from this exploratory study and provides justification for future trials in patients with less advanced disease,'' George Demetri of Dana-Farber Cancer Institute, principal investigator for the study, said in a press release. Enrollment in the breast cancer study will be completed early next year with 40 to 50 patients. The company said additional Phase II clinical results from Incel trials in other tumors, which it expects to be available in 1999, will help the company select the most appropriate regimens and indications for Phase III clinical development. Vertex said the Phase II clinical trial data were reported today at the 21st annual Breast Cancer Symposium in San Antonio, Texas.